Evaluate Efficacy and Safety Of Tolterodine Extended Release Capsule Compared With Tolterodine Immediate Release Tablet
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
To evaluate efficacy of tolterodine extended release formulation compared with immediate
release formulation in subjects with symptoms of overactive bladder
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.